← All trials
NCT05918861
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 3, 2023
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2027
- First posted
- Jun 26, 2023
- Last posted
- Dec 4, 2023
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DalCor PharmaceuticalsLead sponsor
- The Montreal Health Innovations Coordinating CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.